Featured Research

from universities, journals, and other organizations

Weakened malaria parasites form basis of new vaccine strategy

Date:
September 8, 2011
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical trial in humans.

Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical trial in humans. The research was conducted by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, working in concert with a large team of collaborators.

Related Articles


The findings were published online September 8 in Science.

The parasite that causes malaria, a disease that kills nearly one million people each year, is transmitted to humans via the bite of an infected mosquito. After the bite occurs, infectious malaria parasites in the immature, sporozoite stage of their life cycle travel to the liver, where they multiply and then spread to the rest of the body through the bloodstream.

Researchers led by Stephen L. Hoffman, M.D., of Sanaria Inc., in Rockville, Md., created a candidate malaria vaccine against Plasmodium falciparum, the most deadly of the malaria parasites, by purifying these sporozoites and then weakening them with radiation. In a clinical trial involving 80 healthy adult volunteers, the vaccine, called PfSPZ, was found to be safe and to induce a small immune response when given either intradermally (into the skin) or subcutaneously (under the skin).

In a subgroup of 40 study volunteers who were given varying doses of the vaccine and then challenged with malaria, PfSPZ protected only two volunteers against infection. However, results of follow-up studies in rhesus monkeys and in mice conducted by Robert A. Seder, M.D., of the VRC and his colleagues suggest that changing the method of vaccine delivery might improve protection by inducing specialized immune system cells, known as CD8+ T cells, in the liver, the first site of malaria infection. Specifically, the results of the animal studies indicate that delivering PfSPZ intravenously, or directly into the bloodstream, may induce a significantly stronger immune response in the liver than subcutaneous or intradermal administration and thus may have a much greater effect in actually preventing malaria.

NIAID investigators will be launching a human clinical trial with intravenous PfSPZ this fall. The trial will examine the candidate vaccine's safety and effectiveness and enable researchers to explore how it induces a CD8+ T cell response, so that future vaccine formulations can be optimized.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. E. Epstein, K. Tewari, K. E. Lyke, B. K. L. Sim, P. F. Billingsley, M. B. Laurens, A. Gunasekera, S. Chakravarty, E. R. James, M. Sedegah, A. Richman, S. Velmurugan, S. Reyes, M. Li, K. Tucker, A. Ahumada, A. J. Ruben, T. Li, R. Stafford, A. G. Eappen, C. Tamminga, J. W. Bennett, C. F. Ockenhouse, J. R. Murphy, J. Komisar, N. Thomas, M. Loyevsky, A. Birkett, C. V. Plowe, C. Loucq, R. Edelman, T. L. Richie, R. A. Seder, S. L. Hoffman. Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8 T Cell Immunity. Science, 2011; DOI: 10.1126/science.1211548

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Weakened malaria parasites form basis of new vaccine strategy." ScienceDaily. ScienceDaily, 8 September 2011. <www.sciencedaily.com/releases/2011/09/110908145107.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2011, September 8). Weakened malaria parasites form basis of new vaccine strategy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/09/110908145107.htm
NIH/National Institute of Allergy and Infectious Diseases. "Weakened malaria parasites form basis of new vaccine strategy." ScienceDaily. www.sciencedaily.com/releases/2011/09/110908145107.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

More Coverage


Whole-Parasite Malaria Vaccine Shows Promise in Clinical Trial; Vaccine Is First of Its Kind to Earn FDA Approval to Test in Humans

Sep. 9, 2011 — For the first time, a malaria vaccine that uses the entire parasite has proven safe and shown promise to produce a strong immune response in a clinical trial, according to a new study. The vaccine is ... read more

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins